Proactive's Robin Davison publishes fresh research note on Poolbeg Pharma

Proactive research analyst Robin Davison speaks to Thomas Warner after publishing a new report on Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF), following the release of selected data from its human volunteer LPS challenge trial for lead molecule POLB 001.

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  209.77
-0.80 (-0.38%)
AAPL  255.92
+0.29 (0.11%)
AMD  217.50
+7.29 (3.47%)
BAC  49.38
+0.11 (0.22%)
GOOG  294.46
-0.44 (-0.15%)
META  574.46
-4.77 (-0.82%)
MSFT  373.46
+4.09 (1.11%)
NVDA  177.39
+1.64 (0.93%)
ORCL  146.38
+1.15 (0.79%)
TSLA  360.59
-20.67 (-5.42%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.